Natera (NTRA) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary

Business performance and financial outlook

• Achieved record Q1 with over 1 million units, strong volume growth in Signatera and women's health, and raised full-year revenue and gross margin guidance.

• Increased R&D guidance due to faster-than-expected enrollment in early cancer detection studies, shifting spend to 2026 and accelerating market entry.

• Realized pricing and cost of goods sold per unit were strong across the board.

Product innovation and clinical data

• Presented robust data at ASCO, reinforcing Signatera's value in guiding chemotherapy decisions and monitoring patient outcomes.

• Meta-analysis across tumor types and new data in non-small cell lung cancer highlighted expanding clinical utility.

• Announced plans to launch an updated Signatera version with phased variants, aiming for continuous assay improvement.

Market positioning and competitive dynamics

• Maintains market leadership in tumor-informed MRD through clinical evidence, EMR integration, and customer service.

• High patient and clinic stickiness due to personalized, longitudinal monitoring and established workflows.

• Latitude test launched as a reflex option for tissue-free MRD, complementing Signatera and addressing specific clinical scenarios.